socalTECH

JULY 16, 2013

In the latest positive move for the Los Angeles venture capital market, a new investor has moved into town, to take advantage of the area''s growing startup market. The fund has not yet announced local investments, but has been actively talking to companies fitting its investment profile. READ MORE>>.

Capital 174

Capital Southern California Avalon SoCalTech 174

socalTECH

JULY 15, 2010

Investments by venture capitalists in Southern California were up, both in terms of deals and dollars in Q2, according to the latest numbers from PricewaterhouseCoopers and the National Venture Capital Association (NVCA). in 91 investments, up significantly from the $451.8M Nationally, venture deals in the U.S.

Southern California 174

Southern California Orange County Rustic Canyon SoCal 174

socalTECH

DECEMBER 4, 2015

The funding was led by Avalon Ventures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. The startup said it is developing novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types.

UCLA 100

UCLA Avalon San Diego Los Angeles 100

Xconomy

AUGUST 17, 2016

It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp., and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal.

Avalon 40

Avalon San Diego Study Invest 40

socalTECH

JANUARY 19, 2012

The latest numbers from the PricewaterhouseCoopers/National Venture capital Association MoneyTree survey, which is based on data from Thomson Reuters, tallies $738.34M invested in Southern California in Q4 of 2011. The amount is up from $528.0M raised in Q4 of 2010, and up from the $652M invested in the region last quarter.

Southern California 157

Southern California Orange County San Diego GRP Partners 157

Xconomy

JULY 10, 2016

Larry’s diagnosis was cancer with a big C: “I have stage 4 pancreatic cancer and have been on chemo since June with some ups and downs,” he wrote in mid-March. After completing his MBA in 1985, Bock joined a now-defunct venture firm in Costa Mesa, CA. He had great fun doing his companies. They had a lot of fun.”.

San Diego 40

San Diego Startup Avalon Venture Capital 40

Xconomy

JULY 20, 2016

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. It’s a little like what Avalon is doing. But so far, the company has actually drawn only $3 million last year and $4 million earlier this year.

San Diego 40

San Diego Avalon Outsource Development Newsletter 40

socalTECH

APRIL 24, 2015

We caught up with serial entrepreneur Derrick Oien , who is CEO of the company, to learn more. Tell us a little bit about this new startup? Derrick Oien: We started ScoreStream three years ago. It's actually nice that there is a shortage of capital for sports startups. I was at MP3.com,

Media 100

Media Startup Avalon Social Media 100

socalTECH

APRIL 24, 2015

We caught up with serial entrepreneur Derrick Oien , who is CEO of the company, to learn more. Tell us a little bit about this new startup? Derrick Oien: We started Sportstream three years ago. It's actually nice that there is a shortage of capital for sports startups. I was at MP3.com,

Media 100

Media Startup Avalon Social Media 100

Xconomy

JULY 19, 2016

Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. They can’t be made efficiently and at low cost.”.

San Diego 40

San Diego Avalon Research Examples 40

Xconomy

NOVEMBER 14, 2018

Synthetic biology company Synthorx is laying plans for an initial public offering to raise money to advance its suite of enhanced cytokine drugs. The company has applied for a listing on the Nasdaq exchange under the stock. It has now set a preliminary $100 million IPO target in documents filed with securities regulators Tuesday.

San Diego 76

San Diego Product Develop Development 76

Xconomy

APRIL 30, 2018

Synthorx said its improved version of interleukin-2, known as Synthorin IL-2, is at the vanguard in a portfolio of enhanced cytokines the company plans to advance with $63 million in a Series C financing round disclosed today.

Technology 78

Technology Venture Capital San Diego Avalon 78